3 Pharmacy-Led Hospital Group, Imaging Diagnostics and Paediatric Care Stocks With a Strong Future Roadmap: Apollo Hospitals Enterprise, Vijaya Diagnostic Centre and Rainbow Children's Medicare

Hospital and diagnostics stocks let investors follow the organised providers that treat and test patients as demand for quality care grows. Apollo Hospitals Enterprise, Vijaya Diagnostic Centre and Rainbow Children's Medicare cover India's largest private hospital group, a pathology and imaging chain and a network of paediatric and maternity hospitals.

This list covers three hospital and diagnostics stocks with complete current figures: Apollo Hospitals Enterprise, Vijaya Diagnostic Centre and Rainbow Children's Medicare. Every figure comes from the latest reported financials and the 20 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Hospital and Diagnostics Stocks?

Hospital and diagnostics stocks are listed companies that run hospitals, laboratories and imaging centres on a commercial basis. Their earnings depend on bed capacity, occupancy, the mix of procedures and the volume of tests handled.

Hospital and Diagnostics Stocks at a Glance

On valuation, Apollo Hospitals Enterprise and Rainbow Children's Medicare trade at a P/E below the industry P/E, while Vijaya Diagnostic Centre trades above it, which reflects the growth the market already expects. Readers comparing hospital and diagnostics stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in hospital and diagnostics stocks can use the coming numbers to test whether growth is holding.

Why Do Hospital and Diagnostics Stocks Have a Strong Roadmap in India?

Hospital and diagnostics stocks have a strong roadmap in India because spending on treatment and early testing is rising faster than the supply of organised beds and imaging centres.

• Insurance cover. More insured families choose organised providers for planned care.
• Capacity additions. New beds and centres in proven cities lift volumes.
• Specialised care. Paediatric, cardiac and imaging services draw repeat patients.

Why Apollo Hospitals Enterprise Features Among These Hospital and Diagnostics Stocks

Among the hospital and diagnostics stocks on this list, Apollo Hospitals Enterprise is India's largest private healthcare group, running a network of hospitals along with a pharmacy chain, diagnostics, primary care clinics and a digital health platform.

Revenue rose from Rs 14,741 crore in FY22 to Rs 25,420 crore in FY26, a compound annual growth rate of 14.6%. Net profit grew from Rs 1,101 crore in FY22 to Rs 2,003 crore in FY26, which works out to a compound annual growth rate of 16.1%.

In the June 2026 quarter, revenue grew 20.6% year on year to Rs 7,092 crore, while net profit rose 38.4% to Rs 610 crore. The company has a return on equity of 20.5%, a debt to equity ratio of 0.90 and a market capitalisation of Rs 110,757 crore. The stock trades at a P/E of 51.0, below the industry P/E of 59.6.

Roadmap: The company is adding hospital beds in proven cities while growing its pharmacy and digital businesses, which broaden its reach beyond inpatient care. A strong brand in complex treatment and a wide patient base support steady occupancy.

What to watch: Track bed additions and occupancy and the growth of the pharmacy and digital health businesses.

Why Vijaya Diagnostic Centre Features Among These Hospital and Diagnostics Stocks

Among the private hospital shares on this list, Vijaya Diagnostic Centre is a Hyderabad-headquartered diagnostics chain that offers pathology and radiology services through a network of centres, with Hyderabad and Telangana as its home base.

In the June 2026 quarter, revenue grew 22.8% year on year to Rs 240 crore, while net profit rose 37.6% to Rs 53.1 crore. Revenue rose from Rs 475 crore in FY22 to Rs 835 crore in FY26, a compound annual growth rate of 15.1%.

Net profit grew from Rs 111 crore in FY22 to Rs 173 crore in FY26, which works out to a compound annual growth rate of 11.8%. The company has a return on equity of 18.1%, a debt to equity ratio of 0.44 and a market capitalisation of Rs 14,066 crore. The stock trades at a P/E of 75.0, above the industry P/E of 59.6.

Roadmap: The plan is to deepen its network in existing clusters and extend the Vijaya brand into new regions, adding imaging modalities and wellness packages that raise revenue per patient. Diagnostics is a fragmented business, so organised chains with strong brands keep gaining share.

What to watch: Check the revenue contribution from newer regions and the pace at which new centres turn profitable.

Why Rainbow Children's Medicare Features Among These Hospital and Diagnostics Stocks

Among the three companies on this list, Rainbow Children's Medicare operates paediatric, neonatal and maternity hospitals under the Rainbow Children's Hospital and BirthRight by Rainbow brands, with clusters in Hyderabad, Bengaluru, Chennai and Delhi NCR.

The company has a return on equity of 16.9%, a debt to equity ratio of 0.54 and a market capitalisation of Rs 12,554 crore. The stock trades at a P/E of 43.2, below the industry P/E of 59.6.

Revenue rose from Rs 993 crore in FY22 to Rs 1,747 crore in FY26, a compound annual growth rate of 15.2%. Net profit grew from Rs 139 crore in FY22 to Rs 282 crore in FY26, which works out to a compound annual growth rate of 19.4%. In the June 2026 quarter, revenue grew 29.4% year on year to Rs 483 crore, while net profit rose 16.2% to Rs 62.5 crore.

Roadmap: The company adds hospitals in a cluster model, so each new site draws referrals from nearby facilities. Its focus on child and women's healthcare is a defined niche where few organised competitors operate at scale, which helps both pricing and brand recall.

What to watch: Monitor how fast new clusters in Delhi NCR and other regions reach breakeven.

Apollo Hospitals Enterprise vs Vijaya Diagnostic Centre vs Rainbow Children's Medicare on Key Financials

The table below sets the three hospital and diagnostics stocks side by side on revenue, profit and margin, using reported figures.

Apollo Hospitals Enterprise posts the highest return on equity in this group at 20.5%. Apollo Hospitals Enterprise has the largest FY26 revenue at Rs 25,420 crore, and Rainbow Children's Medicare shows the fastest revenue growth with a 15.2% compound annual rate. A useful habit with hospital and diagnostics stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several imaging and paediatric care stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Hospital and Diagnostics Stocks

Every theme carries risks that deserve a check before any decision. For these hospital and diagnostics stocks, the main points are: Long-term private hospital shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Ramp-up timing. New hospitals take time to reach stable occupancy.
• Doctor availability. Expert doctors are central to growth and hard to attract.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter hospital and diagnostics stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Hospital and Diagnostics Stocks

Hospital and diagnostics stocks reward investors who follow bed additions, occupancy and test volumes together. Apollo Hospitals Enterprise, Vijaya Diagnostic Centre and Rainbow Children's Medicare each have a visible expansion path. Based on the 20 October 2026 close, Apollo Hospitals Enterprise trades at Rs 7,700, Vijaya Diagnostic Centre at Rs 1,368.2 and Rainbow Children's Medicare at Rs 1,236. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these hospital and diagnostics stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track hospital and diagnostics stocks, set price alerts and get research-backed stock ideas.

What are hospital and diagnostics stocks?

Ans. Hospital and diagnostics stocks are listed companies that run hospitals, laboratories and imaging centres on a commercial basis. Their earnings depend on bed capacity, occupancy, the mix of procedures and the volume of tests handled. This list looks at three of them, Apollo Hospitals Enterprise, Vijaya Diagnostic Centre and Rainbow Children's Medicare, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.

Which hospital and diagnostics stocks are covered in this list?

Ans. This list covers Apollo Hospitals Enterprise, Vijaya Diagnostic Centre and Rainbow Children's Medicare. Based on the 20 October 2026 close, Apollo Hospitals Enterprise traded at Rs 7,700, Vijaya Diagnostic Centre at Rs 1,368.2 and Rainbow Children's Medicare at Rs 1,236. Their return on equity ranges from 16.9% to 20.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 14.6% to 15.2%.

Why do hospital and diagnostics stocks have a strong future roadmap in India?

Ans. Hospital and diagnostics stocks have a strong roadmap in India because spending on treatment and early testing is rising faster than the supply of organised beds and imaging centres. The main drivers are as follows. Insurance cover. More insured families choose organised providers for planned care. Capacity additions. New beds and centres in proven cities lift volumes. Specialised care. Paediatric, cardiac and imaging services draw repeat patients. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Apollo Hospitals Enterprise performed financially?

Ans. Revenue rose from Rs 14,741 crore in FY22 to Rs 25,420 crore in FY26, a compound annual growth rate of 14.6%. Net profit grew from Rs 1,101 crore in FY22 to Rs 2,003 crore in FY26, which works out to a compound annual growth rate of 16.1%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 7,092 crore, while net profit rose 38.4% to Rs 610 crore. The company has a return on equity of 20.5%, a debt to equity ratio of 0.90 and a market capitalisation of Rs 110,757 crore. The stock trades at a P/E of 51.0, below the industry P/E of 59.6. Looking ahead, the company is adding hospital beds in proven cities while growing its pharmacy and digital businesses, which broaden its reach beyond inpatient care. A strong brand in complex treatment and a wide patient base support steady occupancy.

How has Vijaya Diagnostic Centre performed financially?

Ans. Revenue rose from Rs 475 crore in FY22 to Rs 835 crore in FY26, a compound annual growth rate of 15.1%. Net profit grew from Rs 111 crore in FY22 to Rs 173 crore in FY26, which works out to a compound annual growth rate of 11.8%. In the June 2026 quarter, revenue grew 22.8% year on year to Rs 240 crore, while net profit rose 37.6% to Rs 53.1 crore. The company has a return on equity of 18.1%, a debt to equity ratio of 0.44 and a market capitalisation of Rs 14,066 crore. The stock trades at a P/E of 75.0, above the industry P/E of 59.6. Looking ahead, the plan is to deepen its network in existing clusters and extend the Vijaya brand into new regions, adding imaging modalities and wellness packages that raise revenue per patient. Diagnostics is a fragmented business, so organised chains with strong brands keep gaining share.

How has Rainbow Children's Medicare performed financially?

Ans. Revenue rose from Rs 993 crore in FY22 to Rs 1,747 crore in FY26, a compound annual growth rate of 15.2%. Net profit grew from Rs 139 crore in FY22 to Rs 282 crore in FY26, which works out to a compound annual growth rate of 19.4%. In the June 2026 quarter, revenue grew 29.4% year on year to Rs 483 crore, while net profit rose 16.2% to Rs 62.5 crore. The company has a return on equity of 16.9%, a debt to equity ratio of 0.54 and a market capitalisation of Rs 12,554 crore. The stock trades at a P/E of 43.2, below the industry P/E of 59.6. Looking ahead, the company adds hospitals in a cluster model, so each new site draws referrals from nearby facilities. Its focus on child and women's healthcare is a defined niche where few organised competitors operate at scale, which helps both pricing and brand recall.

What risks should investors check before buying hospital and diagnostics stocks?

Ans. Investors should check a few risks before buying hospital and diagnostics stocks. Ramp-up timing. New hospitals take time to reach stable occupancy. Doctor availability. Expert doctors are central to growth and hard to attract. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of hospital and diagnostics stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.